Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.